Infrastructure Partners
Trusted Advisors to emerging healthcare IT and applied sciences companies
The choice of an investment banker is an important one. Unlike law firms, a banker (or m&a advisor) does not have to screen prospective clients for conflicts of interest. The pursuit of inspired non-zero-sum games in business, while foreign to most lawyers (especially the plaintiff’s bar) should be preserved when possible.
Relationships are important, to be sure, yet over reliance on “relationships” does not always serve the client’s interest. One needn’t look further than 2008 when the largest investment banks did not mark credit default swaps to their appropriate value as they simultaneously unloaded their MBS/CDO positions - while purchasing the very same insurance contracts (swaps) on a RICO basis.
While we see the best in every business case, we consider it our duty to understand quantitative (and qualitative) exposures adverse to our client’s interests, however they present.
To our select few clients, we pledge our consistent, around-the-clock attention to your inspired work.
-Cindy Luxem
Managing Partner/Shareholder
Areas of Practice
Healthcare IT
While Kansas City may strike many in the “start-up” community as flyover land, they forget that a “Samurai” in Silicon Valley saw genius where healthcare IT should be crafted alongside infrastructure for the sake of expediency and innovation. His homage to a fallen Kansas City luminary has not fallen on covered ears. Where one of a small handful of communications infrastructure giants still reigns supreme (for the time being), we commit to bringing you sensible opportunities to invest in parallel with your infrastructure.
When did you first hear about Rapamycin? mTor inhibitors will play a key role in abating the disastrous effects of glycemic metabolism on populations across the world. Yet, entire industries continue to rely on disease as a source of wealth - from food manufacturers, pharmaceutical manufacturers, to hospitals.
When Valter Longo took the Nobel for a “fasting mimicking diet”, legacy food/pharma manufacturers had an opportunity to adjust their offering to this most important finding.
When tears were shed by Peter Attia for not hearing a diabetic patient’s cry for help - seeing their woes as lack of dedication to “exercise and eat right”, it struck a small group of listeners as it should have: an inspired physician’s humble apology and request for forgiveness - his promise to always favor science over bias, even in the face of seemingly insurmountable resistance.
To our buy/investor-side colleagues, we pledge our tireless commitment to providing you: “big pharma”, food scientists, and care providers with sage advice (in concert with deal flow): these are your opportunities to hedge and benefit financially from doing right by the populations which you have been entrusted to steward.